376 results match your criteria: "Groupe Hospitalier Diaconesses- Croix-Saint-Simon[Affiliation]"

Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

JNCI Cancer Spectr

December 2024

Department of Medical and Surgical Oncology & Hematology, Institut of Cancer Strasbourg (ICANS), Strasbourg, France.

Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been reported in prospective trials or routine practice.

Methods: In the real-life multicenter NiQoLe study, patients with PSROC received ISD maintenance niraparib.

View Article and Find Full Text PDF

Background And Aims: Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments.

View Article and Find Full Text PDF

Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?

Arch Pathol Lab Med

December 2024

From the Department of Pathology, Université Paris Cité, Faculté de Médecine Paris Cité, APHP, Centre, Hôpital Cochin, Paris, France (Kime, Just).

Context.—: A correlation between the morphology of ovarian high-grade serous carcinomas (HGSOCs) and BRCA mutations has been previously reported.

Objective.

View Article and Find Full Text PDF

Objective: Ampullary neoplastic lesions can be resected by endoscopic papillectomy (EP) or transduodenal surgical ampullectomy (TSA) while pancreaticoduodenectomy is reserved for more advanced lesions. We present the largest retrospective comparative study analysing EP and TSA.

Design: Of all patients in the database, lesions with prior interventions, benign histology advanced malignancy (T2 and more), patients with hereditary syndromes and those undergoing pancreatoduodenectomy were excluded.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between hip mobility and spinopelvic tilt, finding that higher hip movement (∆PFA ≥ 95°) significantly increases the risk of adverse spinopelvic mobility when transitioning from standing to seated positions.
  • 337 patients undergoing total hip arthroplasty (THA) were analyzed using x-rays to measure spinopelvic tilt (∆SPT) and pelvic femoral angle (∆PFA), demonstrating distinct differences in these measurements based on patient mobility levels.
  • Results indicate that patients with high hip mobility are at a much greater risk of experiencing significant spinopelvic mobility issues, suggesting the importance of assessing hip function before surgery to manage potential complications.
View Article and Find Full Text PDF

Diagnostic and prognostic performance of positron emission tomography/computed tomography in eosinophilic fasciitis: An observational multicenter retrospective study.

J Am Acad Dermatol

November 2024

Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; APHP-CUP, Hôpital Cochin, Université Paris Cité, Paris, France. Electronic address:

View Article and Find Full Text PDF

Introduction: Dupuytren's disease is a benign disorder leading to flexion contracture of the fingers and functional disability. Many treatments have been described. Open fasciectomy is the gold standard; however percutaneous needle fasciotomy (PNF) is a reliable option for uncomplicated primary contracture but it has a high rate of recurrence.

View Article and Find Full Text PDF

Purpose: To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.

Methods: The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months.

View Article and Find Full Text PDF

Background: The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after a prior systemic therapy. This study aims to describe the efficacy and safety of encorafenib/cetuximab +/- binimetinib in patients with BRAF V600E-mutated mCRC in a real-world setting.

Patients And Methods: This retrospective study included patients with BRAF V600E-mutated mCRC who received this combination from January 2020 to June 2022 in 30 centers.

View Article and Find Full Text PDF

[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].

Bull Cancer

September 2024

IUCT Oncopôle Toulouse, service d'urologie, Toulouse, France; Clinique La Croix du Sud, UROSUD, Toulouse, France.

Castration-resistant metastatic prostate cancer remains lethal and a therapeutic challenge. Current strategies are geared towards the personalization of treatments based on the identification of relevant molecular targets, including genomic alterations involved in tumoral processes. Among these novel targeted therapies, poly-ADP-ribose polymerase inhibitors (PARPi), by blocking the action of enzymes involved in deoxyribonucleic acid (DNA) repair, induce the destruction of cells carrying defects in homologous recombination repair, often associated with alterations in genes involved in this mechanism.

View Article and Find Full Text PDF
Article Synopsis
  • - Ovarian cancer is a major cause of death among gynecological cancers, and platinum-based chemotherapy is the primary treatment method, along with maintenance strategies to extend chemotherapy intervals.
  • - Current maintenance treatments include bevacizumab and poly ADP-ribose polymerase inhibitors, but these can only be used once during the disease's progression, leaving a gap in treatment for patients experiencing relapses.
  • - A new international Phase II trial is exploring a combination of a therapeutic cancer vaccine (OSE2101) and anti-PD1 (pembrolizumab) as a maintenance therapy for patients with platinum-sensitive recurrences, regardless of prior treatments.
View Article and Find Full Text PDF

We assessed cumulative detection and determinants of anal high-grade squamous intraepithelial lesions (HSILs) in men who have sex with men living with human immunodeficiency virus and who underwent 3 visits over 2 years, with cytology and high-resolution anoscopy, within the ANRS-EP57-APACHES study. The cumulative HSIL detection rate was 33% (134 of 410), of which 48% HSILs were detected at baseline. HSIL detection varied considerably by center (from 13% to 51%).

View Article and Find Full Text PDF

Introduction: The position of the pelvis in the sagittal plane can vary considerably between different functional positions. Adapting the position of the acetabular cup in relation to the alignment between the spine and the hip of each individual, prior to prosthesis placement, can prevent the risk of prosthetic impingement. Taken individually, risk factors for unfavorable spinopelvic kinematics can be difficult to interpret when trying to precisely predict which patients are at risk.

View Article and Find Full Text PDF

This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment for a maximum of 2 years. Postoperative bevacizumab was optional.

View Article and Find Full Text PDF

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

N Engl J Med

July 2024

From Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and the Belgium and Luxembourg Gynaecological Oncology Group, Leuven (I.V., E.V.N.), and Centre Hospitalier Universitaire de Liège, Liege (C.G.) - all in Belgium; Cancer Center Clínica Universidad de Navarra (A.G.-M.), Hospital Universitario 12 de Octubre (L.M.), and Grupo Español de Investigación en Cáncer de Ovario (GEICO) (A.G.-M.), Madrid, and Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona (A.O.) - all in Spain; Saitama Medical School International Medical Center, Saitama (K.F., K.H.), and the National Cancer Center Hospital, Tokyo (K.Y.) - both in Japan; Centre Hospitalier Universitaire de Besançon, Besançon (E.K.), and GINECO (E.K., A.A.) and Groupe Hospitalier Diaconesses Croix Saint-Simon (A.A.), Paris - all in France; Országos Onkológiai Intézet, Budapest, Hungary (A.B.); Georgia Cancer Center, Augusta University, Augusta (S.G.); Yonsei University College of Medicine (J.-Y.L.) and Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.) - both in Seoul, South Korea; the Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London (S.B.), and the Christie NHS Foundation Trust, Clinical Oncology, Manchester (L.B.) - both in the United Kingdom; Hospital Beneficencia Portuguesa de São Paulo (F.C.M.), Hospital Israelita Albert Einstein de São Paulo (F.C.M.), and Instituto Brasileiro de Controle do Câncer (F.M.C.) - all in Sao Paulo; Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome (D.L.); Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.W.); Amsterdam University Medical Centers, Amsterdam (A.W.); Sunnybrook Research Institute, Toronto (A.C.); Medica Oncólogia Clinica en Grupo Gamma, Rosario, Argentina (M.R.); Skåne University Hospital and Lund University, Lund, Sweden (M.B.); First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic (D.C.); Pfizer, Bothell, WA (L.N., M.S.L.T., E.W.); Genmab US, Princeton, NJ (I.S.); and Mount Sinai Medical Center, Miami Beach, FL (B.M.S.).

Article Synopsis
  • Recurrent cervical cancer poses serious health risks, especially after initial treatment, leading to the need for new therapy options.
  • A phase 3 trial compared the effects of tisotumab vedotin to standard chemotherapy in 502 patients with recurrent or metastatic cervical cancer, focusing on overall survival.
  • Results show that tisotumab vedotin significantly improved median overall survival (11.5 months vs. 9.5 months) and progression-free survival (4.2 months vs. 2.9 months), with a higher response rate compared to chemotherapy, despite both groups experiencing a high incidence of adverse events.
View Article and Find Full Text PDF

Background: Cutibacterium acnes is an anaerobic bacterium mostly implicated in cutaneous and body-implant infections. Splenic abscess is a rare entity and C. acnes abscesses have only exceptionally been reported.

View Article and Find Full Text PDF
Article Synopsis
  • * A review of 116 patients treated with darvadstrocel showed that 44% achieved clinical remission, while 29% experienced deep remission after a median follow-up of 11 months, with some patients needing further surgery.
  • * Factors like higher fistula location and younger age were associated with better treatment outcomes, but overall, complete remission rates remain below 50%, highlighting a notable need for ongoing interventions.
View Article and Find Full Text PDF

Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study.

Clin Colorectal Cancer

December 2024

Sorbonne université, Departement of Medical Oncology, Saint Antoine Hospital, APHP, Paris, France; INSERM, Unité Mixte de Recherche Scientifique 938 and SIRIC CURAMUS, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Sorbonne Université, Paris, France. Electronic address:

Background: Stage II colon cancer (CC) exhibits considerable prognostic heterogeneous. Our objective was to assess survival but also the prognosis impact of microsatellite instability (MSI) in patients with stage IIC (T4bN0M0) CC.

Patients And Methods: We conducted a retrospective observational study including all patients who had primary stage IIC CC resection between 2010 and 2020 in 2 expert centers.

View Article and Find Full Text PDF

Objectives: Nontuberculous mycobacteria (NTM) bone and joint infections (BJIs) are uncommon. We evaluated the characteristics of BJIs and identified differences according to immune status.

Methods: We performed a multicenter retrospective study in France involving patients with documented NTM BJI over a 9-year period.

View Article and Find Full Text PDF

[Should we screen vasa praevia?].

Gynecol Obstet Fertil Senol

December 2024

Département d'obstétrique et gynécologie, hôpital américain de Paris, 92200 Neuilly-sur-Seine, France; Inserm, équipe U1018, épidémiologie clinique, CESP, université Paris-Saclay, UVSQ, 78180 Montigny-le-Bretonneux, France.

View Article and Find Full Text PDF

Aseptic meningitis and Fabry disease.

Ann Clin Transl Neurol

June 2024

Internal Medicine Department, Reference Centre for Lysosomal Diseases, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.

Article Synopsis
  • Fabry disease results from a deficiency in the enzyme alpha-galactosidase A, leading to a buildup of glycosphingolipids and causing various health issues, including neurologic symptoms like neuropathic pain and strokes, with aseptic meningitis being a potential complication.
  • A study reviewed patients from 1995 to 2023, finding that 3.7% experienced aseptic meningitis, with additional data from published cases leading to a total of 29 patients analyzed, predominantly young adults.
  • The findings indicate that many of these patients were unaware they had Fabry disease before their meningitis episode, and the underlying causes of the inflammation in these cases are still not fully understood.
View Article and Find Full Text PDF

Mass cytometry reveals atypical immune profile notably impaired maturation of memory CD4 T with Gb3-related CD27 expression in CD4 T cells in Fabry disease.

J Inherit Metab Dis

July 2024

Centre de Recherche en Myologie, Unité Mixte de Recherche Scientifique 974, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Article Synopsis
  • * A study analyzed immune cells from 41 male Fabry patients and 20 controls, revealing that FD patients show higher expression of specific markers (CD27 and CD28) in certain T cells, which correlates with the levels of harmful lipids (lysoGb3 and Gb3) in the blood.
  • * Treatment with agalsidase beta was found to increase Natural Killer cell proportions, suggesting potential new biomarker correlations that could enhance understanding and management of Fabry disease.
View Article and Find Full Text PDF